BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28894136)

  • 1. Soluble intercellular adhesion molecule-1 is associated with hepatocellular carcinoma risk: multiplex analysis of serum markers.
    Chen VL; Le AK; Podlaha O; Estevez J; Li B; Vutien P; Chang ET; Rosenberg-Hasson Y; Pflanz S; Jiang Z; Ge D; Gaggar A; Nguyen MH
    Sci Rep; 2017 Sep; 7(1):11169. PubMed ID: 28894136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of hepatitis C virus infection on circulating levels of sICAM-1 and VEGF in patients with hepatitis C and hepatocellular carcinoma (HCC) and their role in enhancing detection of HCC.
    Helaly GF; Abou Shamaa LA
    Egypt J Immunol; 2006; 13(1):27-38. PubMed ID: 17974148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of human intercellular adhesion molecule 1 in the blood is useful for predicting the occurrence of hepatocellular carcinomas from chronic hepatitis C and liver cirrhosis.
    Moriyama M; Matsumura H; Shioda J; Aoki H; Nakamura H; Arakawa Y; Nirei K; Yamagami H; Kaneko M; Tanaka N; Arakawa Y
    Intervirology; 2006; 49(6):327-38. PubMed ID: 16926545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum concentration of intercellular adhesion molecule-1 in patients with hepatocellular carcinoma is a marker of the disease progression and prognosis.
    Shimizu Y; Minemura M; Tsukishiro T; Kashii Y; Miyamoto M; Nishimori H; Higuchi K; Watanabe A
    Hepatology; 1995 Aug; 22(2):525-31. PubMed ID: 7543436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early detection of hepatocellular carcinoma co-occurring with hepatitis C virus infection: A mathematical model.
    Zekri AR; Youssef AS; Bakr YM; Gabr RM; Ahmed OS; Elberry MH; Mayla AM; Abouelhoda M; Bahnassy AA
    World J Gastroenterol; 2016 Apr; 22(16):4168-82. PubMed ID: 27122667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients.
    Mak LY; To WP; Wong DK; Fung J; Liu F; Seto WK; Lai CL; Yuen MF
    World J Gastroenterol; 2019 Mar; 25(11):1398-1408. PubMed ID: 30918432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis.
    Chien J; Liu J; Lee MH; Jen CL; Batrla-Utermann R; Lu SN; Wang LY; You SL; Yang HI; Chen CJ
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1971-1977. PubMed ID: 27118149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication.
    Huang CF; Yeh ML; Tsai PC; Hsieh MH; Yang HL; Hsieh MY; Yang JF; Lin ZY; Chen SC; Wang LY; Dai CY; Huang JF; Chuang WL; Yu ML
    J Hepatol; 2014 Jul; 61(1):67-74. PubMed ID: 24613362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High level of intercellular adhesion molecule-1 affects prognosis of patients with hepatocellular carcinoma.
    Zhu PP; Yuan SG; Liao Y; Qin LL; Liao WJ
    World J Gastroenterol; 2015 Jun; 21(23):7254-63. PubMed ID: 26109813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural history of chronic hepatitis B REVEALed.
    Chen CJ; Yang HI
    J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia.
    Paik N; Sinn DH; Lee JH; Oh IS; Kim JH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Liver Int; 2018 Jan; 38(1):68-75. PubMed ID: 28581248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating intercellular adhesion molecule-1 in chronic liver disease and hepatocellular carcinoma.
    Huang YS; Wu JC; Chan CY; Chao Y; Chang FY; Lee SD
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Aug; 62(8):487-95. PubMed ID: 10462824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis.
    Ganne-Carrié N; Chastang C; Chapel F; Munz C; Pateron D; Sibony M; Dény P; Trinchet JC; Callard P; Guettier C; Beaugrand M
    Hepatology; 1996 May; 23(5):1112-8. PubMed ID: 8621142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum soluble urokinase plasminogen activator receptor as a screening test for the early diagnosis of hepatocellular carcinoma.
    Chounta A; Ellinas C; Tzanetakou V; Pliarhopoulou F; Mplani V; Oikonomou A; Leventogiannis K; Giamarellos-Bourboulis EJ
    Liver Int; 2015 Feb; 35(2):601-7. PubMed ID: 25348952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.
    Chiaramonte M; Stroffolini T; Vian A; Stazi MA; Floreani A; Lorenzoni U; Lobello S; Farinati F; Naccarato R
    Cancer; 1999 May; 85(10):2132-7. PubMed ID: 10326690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of serum biological markers in patients with hepatocellular carcinoma.
    Parasole R; Izzo F; Perrone F; Pignata S; Galati MG; Leonardi E; Castiglione F; Orlando R; Castello G; Esposito G; Gallo C; Daniele B
    Clin Cancer Res; 2001 Nov; 7(11):3504-9. PubMed ID: 11705869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-Related Death in Men With Chronic Hepatitis B: A Large Cohort Study.
    Yu MW; Lin CL; Liu CJ; Yang SH; Tseng YL; Wu CF
    Gastroenterology; 2017 Oct; 153(4):1006-1017.e5. PubMed ID: 28711626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
    Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Tanaka J
    J Gastroenterol Hepatol; 2017 Feb; 32(2):451-458. PubMed ID: 27288655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of several cytokines and adhesion molecules in the diagnosis and prediction of survival of hepatocellular carcinoma.
    Iliaz R; Akyuz U; Tekin D; Serilmez M; Evirgen S; Cavus B; Soydinc H; Duranyildiz D; Karaca C; Demir K; Besisik F; Kaymakoglu S; Akyuz F
    Arab J Gastroenterol; 2016 Dec; 17(4):164-167. PubMed ID: 27916547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.